Author:
Healy Elise,Means Arianna Rubin,Knudtson Kelly,Frank Noah,Juarez Alexa,Prohaska Stephanie,McKnight Courtney,Des Jarlais Don,Asher Alice,Glick Sara N.
Abstract
Abstract
Background
Syringe services programs (SSPs) provide harm reduction supplies and services to people who use drugs and are often required by funders or partners to collect data from program participants. SSPs can use these data during monitoring and evaluation (M&E) to inform programmatic decision making, however little is known about facilitators and barriers to collecting and using data at SSPs.
Methods
Using the Consolidated Framework for Implementation Research (CFIR), we conducted 12 key informant interviews with SSP staff to describe the overall landscape of data systems at SSPs, understand facilitators and barriers to data collection and use at SSPs, and generate recommendations for best practices for data collection at SSPs. We used 30 CFIR constructs to develop individual interview guides, guide data analysis, and interpret study findings.
Results
Four main themes emerged from our analysis: SSP M&E systems are primarily designed to be responsive to perceived SSP client needs and preferences; SSP staffing capacity influences the likelihood of modifying M&E systems; external funding frequently forces changes to M&E systems; and strong M&E systems are often a necessary precursor for accessing funding.
Conclusions
Our findings highlight that SSPs are not resistant to data collection and M&E, but face substantial barriers to implementation, including lack of funding and disjointed data reporting requirements. There is a need to expand M&E-focused funding opportunities, harmonize quantitative indicators collected across funders, and minimize data collection to essential data points for SSPs.
Funder
Centers for Disease Control and Prevention
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878–92.
2. Lambdin BH, Bluthenthal RN, Wenger LD, Wheeler E, Garner B, Lakosky P, et al. Overdose Education and Naloxone Distribution within Syringe Service Programs - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1117–21.
3. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9(9):CD012021.
4. 2022 Viral Hepatitis surveillance report. Centers for Disease Control and Prevention, United States, 2022. https://www.cdc.gov/hepatitis/statistics/2022surveillance/index.htm
5. Syringe services programs. Centers for Disease Control and Prevention, 2024. https://www.cdc.gov/syringe-services-programs/php/index.html